Hyderabad : Dr Reddy's Labs has announced that the United States Food & Drug Administration (USFDA) has completed a GMP inspection with zero observations at its API facility (CTO-SEZ) in Srikakulam, Andhra Pradesh.

The inspection was carried out between 10th November and 14th November, 2025.

Established in 1984, Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India. The Company offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddy's Labs major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe.

Read also: Dr. Reddy

See Full Page